Zhaoke Ophthalmology (“Zhaoke”), an ophthalmic specialized pharmaceutical company in China, recently submitted its A1-filing for Hong Kong Stock Exchange IPO. Zhaoke owns 23 ophthalmic research products comprising 11 innovative and 12 generic drug products. Core products include cyclosporine A ophthalmic gel to cure dry eye syndrome and ZKY001, an eye drop targeting corneal epithelial defects.

VMS invested in Zhaoke’s series A and B financing in 2019 and 2020, respectively.

If you would like to hear the latest updates on the Firm and the Fund, please feel free to contact our Investor Relations team at IR@VMSIG.COM.